Emil Kakkis
Emil Kakkis is a renowned medical doctor and biomedical researcher known for his significant contributions to the field of rare diseases. He is the founder and CEO of Ultragenyx Pharmaceutical, a company dedicated to the development of novel products for the treatment of rare and ultra-rare diseases.
Early Life and Education
Emil Kakkis was born and raised in California, United States. He completed his undergraduate studies in biology at the University of California, Berkeley and later pursued his medical degree and PhD in Biomedical Sciences from the University of California, Los Angeles.
Career
After completing his education, Kakkis began his career as a clinical researcher at BioMarin Pharmaceutical, where he developed the first approved treatments for the rare diseases Mucopolysaccharidosis I (MPS I) and Phenylketonuria (PKU).
In 2010, Kakkis founded Ultragenyx Pharmaceutical with the aim of developing treatments for rare and ultra-rare genetic diseases. Under his leadership, the company has developed and commercialized several innovative therapies for diseases that previously had no approved treatments.
Contributions to Medicine
Kakkis is widely recognized for his pioneering work in the field of rare diseases. His research has led to the development of several groundbreaking therapies, significantly improving the quality of life for patients suffering from these conditions.
In addition to his work at Ultragenyx, Kakkis is also the founder of the EveryLife Foundation for Rare Diseases, a non-profit organization dedicated to advancing the development of treatment and diagnostic opportunities for rare disease patients.
Awards and Recognition
Over the course of his career, Kakkis has received numerous awards and recognition for his contributions to medicine and rare disease research. These include the National Organization for Rare Disorders (NORD) Lifetime Achievement Award and the Global Genes RARE Champion of Hope Award.
See Also
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
